MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
4.000
-0.310
-7.19%
After Hours: 3.950 -0.05 -1.25% 17:40 02/07 EST
OPEN
4.250
PREV CLOSE
4.310
HIGH
4.290
LOW
3.910
VOLUME
21.89K
TURNOVER
--
52 WEEK HIGH
399.60
52 WEEK LOW
3.650
MARKET CAP
5.83M
P/E (TTM)
-0.0045
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APVO last week (0127-0131)?
Weekly Report · 5d ago
Weekly Report: what happened at APVO last week (0120-0124)?
Weekly Report · 01/27 10:17
Weekly Report: what happened at APVO last week (0113-0117)?
Weekly Report · 01/20 10:13
Weekly Report: what happened at APVO last week (0106-0110)?
Weekly Report · 01/13 10:13
Weekly Report: what happened at APVO last week (1230-0103)?
Weekly Report · 01/06 10:18
Weekly Report: what happened at APVO last week (1223-1227)?
Weekly Report · 12/30/2024 10:14
Weekly Report: what happened at APVO last week (1216-1220)?
Weekly Report · 12/23/2024 10:18
Aptevo Therapeutics (APVO) Receives a Buy from Roth MKM
TipRanks · 12/20/2024 18:41
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.